Literature DB >> 11077616

Evaluation and treatment of low responders in assisted reproductive technology: a challenge to meet.

S J Fasouliotis1, A Simon, N Laufer.   

Abstract

PURPOSE: To investigate the various methods of evaluation and treatment of patients with a low response to controlled ovarian hyperstimulation in assisted reproductive technologies (ART).
METHODS: Review and analysis of relevant studies published in the last decade, identified through the literature and Medline searches.
RESULTS: While a universally accepted definition for low responders is still lacking, these patients are reported to represent about 10% of the ART population. Several ovarian reserve screening techniques have been proposed; however, currently the best-characterized and most sensitive screening tools available are the basal day 3 serum follicle-stimulating hormone level and the clomiphene citrate challenge test. When abnormal, these tests allow physicians to counsel patients that their prognosis for conception is poor. Although the presence of a normal result does indicate better long-term chances for conception, on age-related decline in fecundity remains and patient age should still be considered when counseling patients with normal screening results. Several stimulation protocols have been applied in the low-response group with varying success. Recent studies show that the use of a minidose gonadotropin-releasing hormone-agonist protocol may result in significantly decreased cycle cancellations as well as increased clinical and ongoing pregnancies, and thus is proposed as a first-line therapy. Studies evaluating supplementary forms of treatment to the ovulation induction regimen show improved outcome when pretreating with oral contraceptives, whereas there seems to be no benefit from cotreatment with growth hormone or glucocorticoids. Blastocyst culture and transfer and assisted hatching in low responders are still under evaluation, whereas natural cycle in vitro fertilization may be used in cases of repeated failures as a last option before resorting to oocyte donation or adoption. Future possible forms of treatment like in vitro maturation of immature human oocytes, cytoplasm, and nuclear transfer currently are experimental in nature and their efficacy has still to be proven.
CONCLUSIONS: The evaluation and treatment of low responders in ART remains a challenge. Understanding of the underlying etiology and pathophysiology of this disorder may help the clinician to approach it successfully.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11077616      PMCID: PMC3489420          DOI: 10.1023/a:1009465324197

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  95 in total

1.  Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause.

Authors:  M J Faddy; R G Gosden; A Gougeon; S J Richardson; J F Nelson
Journal:  Hum Reprod       Date:  1992-11       Impact factor: 6.918

2.  High dosages of gonadotropins are associated with poor pregnancy outcomes after in vitro fertilization-embryo transfer.

Authors:  L Stadtmauer; E C Ditkoff; D Session; A Kelly
Journal:  Fertil Steril       Date:  1994-06       Impact factor: 7.329

Review 3.  Treatment of low responders.

Authors:  S J Muasher
Journal:  J Assist Reprod Genet       Date:  1993-02       Impact factor: 3.412

4.  The poor-responder patient in an in vitro fertilization-embryo transfer program.

Authors:  Z Ben-Rafael; D Feldberg
Journal:  J Assist Reprod Genet       Date:  1993-02       Impact factor: 3.412

5.  Prediction of response to controlled ovarian hyperstimulation: a comparison of basal and clomiphene citrate-stimulated follicle-stimulating hormone levels.

Authors:  T Tanbo; P O Dale; O Lunde; N Norman; T Abyholm
Journal:  Fertil Steril       Date:  1992-04       Impact factor: 7.329

6.  Randomized, prospective comparison of luteal leuprolide acetate and gonadotropins versus clomiphene citrate and gonadotropins in 408 first cycles of in vitro fertilization.

Authors:  I S Tummon; S A Daniel; B R Kaplan; J A Nisker; A A Yuzpe
Journal:  Fertil Steril       Date:  1992-09       Impact factor: 7.329

7.  Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization.

Authors:  R T Scott; D Navot
Journal:  Fertil Steril       Date:  1994-05       Impact factor: 7.329

Review 8.  The use of gonadotrophin releasing hormone agonists for in vitro fertilization and other assisted procreation techniques: experience from three centres.

Authors:  J Smitz; R Ron-El; B C Tarlatzis
Journal:  Hum Reprod       Date:  1992-06       Impact factor: 6.918

9.  Assessment of ovarian and uterine blood flow by transvaginal color Doppler in ovarian-stimulated women: correlation with the number of follicles and steroid hormone levels.

Authors:  Z Weiner; I Thaler; J Levron; N Lewit; J Itskovitz-Eldor
Journal:  Fertil Steril       Date:  1993-04       Impact factor: 7.329

10.  The relative success of gonadotropin-releasing hormone analogue, clomiphene citrate, and gonadotropin in 1,099 cycles of in vitro fertilization.

Authors:  J Dor; I Ben-Shlomo; D Levran; E Rudak; M Yunish; S Mashiach
Journal:  Fertil Steril       Date:  1992-11       Impact factor: 7.329

View more
  17 in total

1.  A new treatment to avoid severe ovarian hyperstimulation utilizing insights from in vitro maturation therapy.

Authors:  B I Rose
Journal:  J Assist Reprod Genet       Date:  2013-12-01       Impact factor: 3.412

2.  Predicting pregnancy in women undergoing in-vitro fertilization with basal serum follicle stimulating hormone levels between 10.0 and 11.9 IU/L.

Authors:  Dan Levin; Sunny H Jun; Michael H Dahan
Journal:  J Turk Ger Gynecol Assoc       Date:  2015-03-01

3.  Area under the curve for estradiol levels do not consistently reflect estradiol levels on the day of hCG administration in patients undergoing controlled ovarian hyperstimulation for IVF-ET.

Authors:  Mohamed F M Mitwally; Hemlata S Bhakoo; Kent Crickard; Michael W Sullivan; Ronald E Batt; John Yehl
Journal:  J Assist Reprod Genet       Date:  2005-02       Impact factor: 3.412

4.  Mild Versus Conventional Ovarian Stimulation for Poor Responders Undergoing IVF/ICSI.

Authors:  Charalampos Siristatidis; George Salamalekis; Konstantinos Dafopoulos; George Basios; Paraskevi Vogiatzi; Nikolaos Papantoniou
Journal:  In Vivo       Date:  2017 Mar-Apr       Impact factor: 2.155

5.  Effects of prolonging administration gonadotropin on unexpectedly poor ovarian responders undergoing in vitro fertilization.

Authors:  Zhaolian Wei; Xianxia Cheng; Huirong Li; Yunxia Cao; Lin Cong; Ping Zhou; Jun Li
Journal:  Reprod Biol Endocrinol       Date:  2010-03-17       Impact factor: 5.211

Review 6.  Contemporary pharmacological manipulation in assisted reproduction.

Authors:  Judith A F Huirne; Cornelis B Lambalk; Andre C D van Loenen; Roel Schats; Peter G A Hompes; Bart C J M Fauser; Nick S Macklon
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Gonadotropin-releasing hormone (GnRH)-antagonist versus GnRH-agonist in ovarian stimulation of poor responders undergoing IVF.

Authors:  Sozos J Fasouliotis; Neri Laufer; Shelley Sabbagh-Ehrlich; Aby Lewin; Arye Hurwitz; Alex Simon
Journal:  J Assist Reprod Genet       Date:  2003-11       Impact factor: 3.412

8.  Clinical benefit of metaphase I oocytes.

Authors:  Leen Vanhoutte; Petra De Sutter; Josiane Van der Elst; Marc Dhont
Journal:  Reprod Biol Endocrinol       Date:  2005-12-15       Impact factor: 5.211

9.  Predictive value of age-specific FSH levels for IVF-ET outcome in women with normal ovarian function.

Authors:  Tingfeng Fang; Zheng Su; Liangan Wang; Ping Yuan; Ruiqi Li; Nengyong Ouyang; Lingyan Zheng; Wenjun Wang
Journal:  Reprod Biol Endocrinol       Date:  2015-06-17       Impact factor: 5.211

10.  Myo-inositol therapy for poor-responders during IVF: a prospective controlled observational trial.

Authors:  Francesca Caprio; Maria Diletta D'Eufemia; Carlo Trotta; Maria Rosaria Campitiello; Raffaele Ianniello; Daniela Mele; Nicola Colacurci
Journal:  J Ovarian Res       Date:  2015-06-12       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.